Q3 2024 · 13F-HR
Foresite Capital Management IV, LLCholdings as filed
Filed 2024-11-14 · accession 0001104659-24-118737
$153.0M
Reported value
5
Positions
2024-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N69605108 | PHVS | Pharvaris N.V. | $81.4M | 53.2% | 4,397,881 | Common | SOLE |
| 50127T109 | KURA | Kura Oncology, Inc. | $36.1M | 23.6% | 1,849,947 | Common | SOLE |
| 87164F105 | SNDX | Syndax Pharmaceuticals, Inc. | $16.8M | 11.0% | 875,000 | Common | SOLE |
| 55083R104 | — | Lyell Immunopharma, Inc. | $11.5M | 7.51% | 8,325,000 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics Inc. | $7.1M | 4.63% | 1,000,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.